Universal human papillomavirus genotyping by the digene HPV Genotyping RH and LQ Tests

Journal of Clinical Virology

Volumn 50, Issue 4, 2011, Pages 276-280

  Geraets, D T ^a   Lenselink, C H ^b   Bekkers, R L M ^b   van Doorn, L J ^a   Quint, W G V ^a   Melchers, W J G ^b  

^a DDL DIAGNOSTIC LABORATORY   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Amplicor; Genotyping; Human papillomavirus; Luminex xMAP; Reverse hybridization strip

Indexed keywords

ADULT; ARTICLE; FEMALE; GENE AMPLIFICATION; GENOTYPE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 26; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 35; HUMAN PAPILLOMAVIRUS TYPE 39; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 51; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 53; HUMAN PAPILLOMAVIRUS TYPE 56; HUMAN PAPILLOMAVIRUS TYPE 58; HUMAN PAPILLOMAVIRUS TYPE 59; HUMAN PAPILLOMAVIRUS TYPE 66; HUMAN PAPILLOMAVIRUS TYPE 68; HUMAN PAPILLOMAVIRUS TYPE 73; HUMAN PAPILLOMAVIRUS TYPE 82; LQ TEST; MAJOR CLINICAL STUDY; OPEN READING FRAME; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RH TEST; VIRUS DETECTION; VIRUS IDENTIFICATION; WART VIRUS;

ADOLESCENT; ADULT; DNA, VIRAL; EARLY DETECTION OF CANCER; FEMALE; GENOTYPE; HUMANS; LABORATORY TECHNIQUES AND PROCEDURES; MASS SCREENING; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; REAGENT KITS, DIAGNOSTIC; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS; YOUNG ADULT;

EID: 79952628027     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcv.2010.12.011     Document Type: Article

References (21)

1. Sankaranarayanan R., Nene B.M., Shastri S.S., Jayant K., Muwonge R., Budukh A.M., et al. HPV screening for cervical cancer in rural India. N Engl J Med 2009, 360(April (14)):1385-1394.
2. Bulkmans N.W., Rozendaal L., Snijders P.J., Voorhorst F.J., Boeke A.J., Zandwijken G.R., et al. POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44,102 women. Int J Cancer 2004, 110(1):94-101.
3. Ronco G., Giorgi-Rossi P., Carozzi F., Confortini M., Dalla Palma P., Del Mistro A., et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol 2010, 11(March (3)):249-257.
4. Berkhof J., Bulkmans N.W., Bleeker M.C., Bulk S., Snijders P.J., Voorhorst F.J., et al. Human papillomavirus type-specific 18-month risk of high-grade cervical intraepithelial neoplasia in women with a normal or borderline/mildly dyskaryotic smear. Cancer Epidemiol Biomarkers Prev 2006, 15(July (7)):1268-1273.
5. Bulkmans N.W., Berkhof J., Bulk S., Bleeker M.C., van Kemenade F.J., Rozendaal L., et al. High-risk HPV type-specific clearance rates in cervical screening. Br J Cancer 2007, 96(May (9)):1419-1424.
6. Naucler P., Ryd W., Tornberg S., Strand A., Wadell G., Hansson B.G., et al. HPV type-specific risks of high-grade CIN during 4 years of follow-up: a population-based prospective study. Br J Cancer 2007, 97(July (1)):129-132.
7. Hesselink A.T., Bulkmans N.W., Berkhof J., Lorincz A.T., Meijer C.J., Snijders P.J. Cross-sectional comparison of an automated hybrid capture 2 assay and the consensus GP5+/6+ PCR method in a population-based cervical screening program. J Clin Microbiol 2006, 44(October (10)):3680-3685.
8. Jacobs M.V., Snijders P.J., van den Brule A.J., Helmerhorst T.J., Meijer C.J., Walboomers J.M. A general primer GP5+/GP6(+)-mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings. J Clin Microbiol 1997, 35(3):791-795.
9. Hesselink A.T., Heideman D.A., Berkhof J., Topal F., Pol R.P., Meijer C.J., et al. Comparison of the clinical performance of PapilloCheck human papillomavirus detection with that of the GP5+/6+-PCR-enzyme immunoassay in population-based cervical screening. J Clin Microbiol 2010, 48(March (3)):797-801.
10. Meijer C.J., Berkhof J., Castle P.E., Hesselink A.T., Franco E.L., Ronco G., et al. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer 2009, 124(February (3)):516-520.
11. Einstein M.H., Martens M.G., Garcia F.A., Ferris D.G., Mitchell A.L., Day S.P., et al. Clinical validation of the Cervista HPV HR and 16/18 genotyping tests for use in women with ASC-US cytology. Gynecol Oncol 2010, 118(August (2)):116-122.
12. Kinney W., Stoler M.H., Castle P.E. Special commentary: patient safety and the next generation of HPV DNA tests. Am J Clin Pathol 2010, 134(2):193-199.
13. van den Brule A.J., Pol R., Fransen-Daalmeijer N., Schouls L.M., Meijer C.J., Snijders P.J. GP5+/6+ PCR followed by reverse line blot analysis enables rapid and high-throughput identification of human papillomavirus genotypes. J Clin Microbiol 2002, 40(3):779-787.
14. Geraets D.T., Heideman D.A., de Koning M.N., Snijders P.J., Meijer C.J., van Doorn L.J., et al. High genotyping concordance between the digene HPV Genotyping RH Test and the Reverse Line Blot genotyping assay on GP5+/6+-PCR products. J Clin Virol. 2009, 46(November (Suppl. 3)):S16-S20.
15. Geraets D.T., Heideman D.A., de Koning M.N., Snijders P.J., van Alewijk D.C., Meijer C.J., et al. High-throughput genotyping of high-risk HPV by the digene HPV Genotyping LQ Test using GP5+/6+-PCR and xMAP technology. J Clin Virol 2009, 46(November (Suppl. 3)):S21-S26.
16. Lenselink C.H., Melchers W.J., Quint W.G., Hoebers A.M., Hendriks J.C., Massuger L.F., et al. Sexual behaviour and HPV infections in 18 to 29 year old women in the pre-vaccine era in the Netherlands. PLoS One 2008, 3(11):e3743.
17. Kleter B., van Doorn L.J., Schrauwen L., Molijn A., Sastrowijoto S., ter Schegget J., et al. Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus. J Clin Microbiol 1999, 37(8):2508-2517.
18. Meijer C.J., Snijders P.J., Castle P.E. Clinical utility of HPV genotyping. Gynecol Oncol 2006, 103(October (1)):12-17.
19. Stewart D.E., Gagliardi A., Johnston M., Howlett R., Barata P., Lewis N., et al. Self-collected samples for testing of oncogenic human papillomavirus: a systematic review. J Obstet Gynaecol Can 2007, 29(October (10)):817-828.
20. van Ham M.A., Bakkers J.M., Harbers G.K., Quint W.G., Massuger L.F., Melchers W.J. Comparison of two commercial assays for detection of human papillomavirus (HPV) in cervical scrape specimens: validation of the Roche AMPLICOR HPV test as a means to screen for HPV genotypes associated with a higher risk of cervical disorders. J Clin Microbiol 2005, 43(June (6)):2662-2667.
21. Hesselink A.T., van Ham M.A., Heideman D.A., Groothuismink Z.M., Rozendaal L., Berkhof J., et al. Comparison of GP5+/6+-PCR and SPF10-line blot assays for detection of high-risk human papillomavirus in samples from women with normal cytology results who develop grade 3 cervical intraepithelial neoplasia. J Clin Microbiol 2008, 46(October (10)):3215-3221.